Drug Profile
Factor VIII/von Willebrand factor - CSL Behring
Alternative Names: Aleviate; Biostate; VoncentoLatest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Factor VIII replacements; Von willebrand factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia A; Von Willebrand disease
Most Recent Events
- 22 Mar 2022 Discontinued - Phase-III for Haemophilia A (In children) in Guatemala, Lebanon, Mexico (IV)
- 22 Mar 2022 Discontinued - Phase-III for Von Willebrand disease (In children) in Lebanon, Guatemala (IV)
- 27 Aug 2019 No development reported - Phase-III for Haemophilia A (In children) in Guatemala, Lebanon, Mexico (IV)